Study (author, ref.) | TKI-based therapy | No. of patients with CHR | Post-induction MRD (%)1 | ||
---|---|---|---|---|---|
CMR | MMR | ||||
TKI | Chemotherapy | ||||
Daver (2015) [69] | IM | Intensive (Hyper-CVAD) | 51 | 45 (12 weeks) | 38 (median 10 weeks) |
Pfeifer (2010) [63] | Intensive (GMALL) | 247 | 12.5–33 (consolidation 1)2 | – | |
Chalandon (2015) [68] | Intensive (GRAALL)* | 121 | 9.5 (cycle 1) 28.6 (cycle 2) | 43.1 (cycle 1) 66.1 (cycle 2) | |
Non-intensive (GRAALL)* | 133 | 9.9 (cycle 1) 22.6 (cycle 2) | 45.5 (cycle 1) 64.5 (cycle 2) | ||
Vignetti (2007) [79] | None (GIMEMA)3 | 29 | 14 | – | |
Ravandi (2015) [72] | DAS | Intensive (Hyper-CVAD) | 69 | 65 (median 4 weeks) | 28 (median 4 weeks) |
Rousselot (2016) [76] | Non-intensive (EWALL) | 67 | 20 (cycle 1) 24 (cycle 2) | 60 (cycle 1) 65 (cycle 2) | |
Chiaretti (2015) [58] | None (GIMEMA)3 | 58 | 18.6 | – | |
Kim (2015) [73] | NIL | Intensive | 82 | 56 (at CHR) | 79 (at CHR) |
Ottmann (2018) [78] | Non-intensive (EWALL) | 68 | 14 (cycle 1) 58 (consolidation 2) | 41 (cycle 1) 86 (consolidation 2) | |
Chalandon (2018) [77] | Non-intensive (GRAALL) | 60 | – | 80 (cycle 2) 93 (cycle 4) | |
Papayannidis (2013) [81] | IM/NIL | None (GIMEMA)4 | 34 | 35.4 (week 6) 46.6 (week 12) | – |
Jabbour (2018) [75] | PON | Intensive (Hyper-CVAD) | 76 | 83 (median 10 weeks) | 97 (median 3 weeks) |
Martinelli (2017) [83] | None (GIMEMA)3 | 38 | 60.6 | – |